Sveriges Riksbank
| Bid date, 2021-01-21 | |
| Bid Date | 2021-01-21 |
| Bid times | 14.00-14.30 (CET/CEST) on the Bid date |
| Offerent Amount | USD 10 billion |
| Maximum Permitted Volume of Bids | USD 4 billion from an individual institution |
| Settlement Date | 2021-01-25 |
| Minimum Permitted Bid Volume | 100 USD million per bid |
| Maximum Allocation | 40 per cent of the Offerend amount |
| Allocation time | Not later than 15.00 (CET/CEST) on the Bid date |
| Maturity Date | 2021-04-19 |
| Maximum Number of Bids | 10 per individual institution |
| Minimum bid rate | 0.33 % |
| Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-01-19
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd8.11.2025 00:00:00 CET | Press release
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Columbus A/S7.11.2025 23:46:30 CET | Press release
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them
Evaxion7.11.2025 23:10:00 CET | Press release
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
VALLOUREC7.11.2025 18:45:00 CET | Press release
VALLOUREC ANNOUNCES A TRANSITION IN ITS FINANCIAL MANAGEMENT
Trifork Group AG7.11.2025 18:29:08 CET | Press release
52/2025・Trifork Group: Reporting of transactions made by persons discharging managerial responsibilities
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
